PRESS RELEASE [Press release] BioPlus’s 2 types of hyaluronic acid fillers obtained special import license from China
PRESS RELEASE [Press release] This year’s goal is to double the operating profit…Targeting the largest market for filler in the U.S. and China
PRESS RELEASE [Press release] BioPlus signs overall medical device contract with Chimin health management, a medical pharmaceutical specialist in China
PRESS RELEASE [Press release] BioPlus Co-develops Next Generation Botulinum Toxin with ProCell Therapeutics
PRESS RELEASE [Press release] BioPlus’s operating profit in 2021 is 18.3 billion won. “The best performance since its foundation”
PRESS RELEASE [Press release] Co-development MOU with BioPlus, Noblegen, and Gachon University for virus treatments was signed
PRESS RELEASE [Press release] Will BioPlus continue its surprise performance next year? It’s about to enter China, the biggest market
